Genomic Health makes understanding Oncotype DX Colon Recurrence Score test results as easy as possible.
Interactive report guide
Quickly and easily understand how to interpret the Oncotype DX Colon Recurrence Score report.
What the report includes
For each patient, a detailed Colon Recurrence Score report is generated. The individualized report includes:
- A number between 0-100 (the Recurrence Score result) indicating risk of recurrence.
- The likelihood that adjuvant therapy will benefit the patient.
- Supporting information, such as DNA mismatch repair (MMR) status.
The Oncotype Recurrence Score test is most useful for patients who have:
- Anatomic stage II, T3 colon cancer, and whose mismatch repair (MMR) status is MMR-Proficient (MMR-P).
- Anatomic stage III A/B colon cancer.
Understanding the Colon Recurrence Score reports
There are two reports tailored to the patient’s anatomic stage: stage II, MMR-P or stage III A/B.
Anatomic stage II, MMR-P report
The anatomic stage II, MMR-P report consists of two pages that include the following information:
- Page one summarizes the risk of recurrence following surgery alone (from the QUASAR validation study). You’ll see the Colon Recurrence Score result, along with the associated recurrence risk estimate following surgery for MMR-P patients by T-stage. For patients whose Recurrence Score result is ≥ 41, shading in the graph indicates a higher risk.
- Page two shows the risk of recurrence following chemotherapy (from the NSABP C-07 validation study). You’ll see the patient’s Recurrence Score result, now with the associated recurrence risk estimate following 5-FU/LV alone or in combination with oxaliplatin. For patients whose Recurrence Score result is ≥ 41, shading in the graph indicates a higher risk.
Anatomic stage III A/B report
The anatomic stage III A/B report shows risk of recurrence following chemotherapy (from the NSABP C-07 validation study). You’ll see the patient’s Recurrence Score result with the associated recurrence risk estimate following 5-FU/LV alone or in combination with oxaliplatin.
For patients whose Recurrence Score result is < 30, shading indicates the patient is at lower risk and may be considered for 5FU/LV alone to avoid the toxicities of oxaliplatin.
How the score is generated
The Colon Recurrence Score test is a genomic test. The result is based on the expression of 12 genes from tumor tissue removed during surgery. Looking at the activity of this unique set of genes gives information about how likely the cancer is to return and can inform treatment decisions.
The Colon Recurrence Score test is the first and only genomic test for colon cancer with Level 1 evidence.1-4 Learn more about the test and its clinical evidence.
Note: Staging (AJCC 6th ed.) and assay selection at the time of order determines the results presented on the report.
Getting your results
Most Recurrence Score results are available within approximately two weeks from the date laboratory processing begins. Please allow 1-2 additional days for MMR testing. You can access the results through the online physician portal or receive the report by fax.
Start Report Guide
The Recurrence Score® Result is an individualized score from 0–100.
Next to the score is an overview of the patient's risk estimate within 3 and 5 years.
Data-supported prediction of the patient's 3-year recurrence risk*.
*Based on the QUASAR study.
Start Report Guide
On the next page, the patient's 5-year risk of recurrence* with 5-FU/LV with or without oxaliplatin.
*Based on the NSABP C-07 validation study.
Start Report Guide
The last page of the report is designed to help patients understand their results.
Visually explains the patient's personalized risk of recurrence.
Facilitates discussions and treatment decisions.